Barinthus Biotherapeutics (BRNS) Stock Statistics & Valuation Metrics

Barinthus Biotherapeutics has a market cap or net worth of $56.48M. The enterprise value is -$24.67M.

Barinthus Biotherapeutics has 40,339,394 shares outstanding. The number of shares has decreased by -2.65% in one year.

Barinthus Biotherapeutics’s return on equity (ROE) is -0.47 and return on invested capital (ROIC) is -46.33%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Barinthus Biotherapeutics had revenue of 14.97M and earned -61.07M in profits. Earnings per share was -1.55.

In the last 12 months, operating cash flow was -4.90M and capital expenditures -194.77K, giving a free cash flow of -5.09M billion.

Barinthus Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Barinthus Biotherapeutics upcoming earnings date is Aug 7, 2025, After Close (Confirmed).

Barinthus Biotherapeutics as a current ratio of 8.03, with Debt / Equity ratio of 10.32%

In the past 12 months, Barinthus Biotherapeutics has paid -44.00K in taxes.

Barinthus Biotherapeutics EV to EBITDA ratio is 0.92, with an EV/FCF ratio of 1.71.

Barinthus Biotherapeutics has $99.12M in cash and marketable securities with $11.92M in debt, giving a net cash position of -$87.20M billion.

Gross margin is 259.85%, with operating margin of -454.07%, and net profit margin of -408.00%.

The average price target for Barinthus Biotherapeutics is $3.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy